Research Study Proves Calmer Canine Veterinary Therapy

Northvale, N.J., Feb. 07, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — ADM Tronics Unlimited, Inc. (OTCQB: ADMT) announced that a recent North Carolina State University (“NCSU”) study of the Calmer Canine non-invasive electrotherapy device has conclusively demonstrated that it is is an effective treatment for canine separation anxiety (“CSA”).

The NCSU-led study of Calmer Canine in the treatment of dogs with CSA was double-blind, randomized, and placebo-controlled – the “gold standard” for efficacy evaluations of therapeutic technologies. By the fourth week of the study, nearly two-thirds of the dogs showed a 100% greater improvement in time spent resting versus being anxious when home alone. Data collected by video analysis of the dogs when they were alone was analyzed by researchers to more accurately assess the severity of CSA.

The Calmer Canine was developed for Assisi Animal Health (“Assisi”) by ADMT and is manufactured at ADMT’s medical device manufacturing facility in Northvale, NJ. ADMT has also developed and manufactured Assisi’s Veterinary Loop anti-inflammatory therapy devices.

The Calmer Canine is a highly innovative, gentle, effective, safe, and drug-free treatment system for CSA, which is a behavior related to anxiety or fear that occurs when an owner leaves their dog alone. The Calmer Canine device delivers targeted pulsed electromagnetic field (tPEMF) signals non-invasively to the area of ​​the brain responsible for anxiety symptoms. It effectively brings the anxious brain back to a more balanced emotional state with lasting effects.

Canine Calmer, applied as two 15-minute treatments daily for 4-6 weeks, effectively reduces the symptoms of ASC, such as incessant barking, destructive behavior and inappropriate urination. In many cases, results can be seen in a short period of time. In the NCSU study, half of owners reported an improvement in their dog’s anxiety after just one week of treatments.

It is estimated that approximately 17% or 13 million dogs in the United States alone suffer from CSA. Effective, non-invasive, non-pharmaceutical therapy can be a major benefit in reducing shelter abandonment, reducing euthanasia, and dramatically improving the relationship between owners and their dogs.

In addition to resolving CSA, Assisi reports that there is anecdotal evidence that the Calmer Canine reduces many other types of anxiety, from stranger anxiety to noise phobia.

Watch a video about Calmer Canine on this link: https://www.youtube.com/watch?v=X4BSCurq9nE&t=9s

See NCSU study at: https://www.frontiersin.org/articles/10.3389/fvets.2021.775092/full

For more information on Calmer Canine and Loop technologies, visit assisianimalhealth.com. Calmer Canine® is a registered trademark of Assisi Animal Health – all rights reserved.

ADMT welcomes inquiries regarding its electronics and medical device development and manufacturing services at www.admtronics.com.

To receive email updates from ADMT, complete the form at the bottom of the page at this link: https://admtronics.com/investor-relations/

About ADMT

ADMT is a diverse, technology-driven developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, move it through development, manufacturing and marketing, all in-house. ADMT has three business areas: Proprietary Medical Devices; medical device design, engineering, regulatory and manufacturing services; and environmentally friendly water-based formulations. The company’s headquarters, laboratories, FDA-registered medical devices and manufacturing operations are located in Northvale, NJ. ADMT’s multidisciplinary team of engineers, researchers, and technologists utilize state-of-the-art technology infrastructure, such as 3D rapid prototyping, precision instrumentation, and specialized software and peripherals, for research, development, and commercialization of diverse technologies. Additional information is available on the company’s website – admtronics.com.

Except for historical information contained in this press release, the matters set forth in this press release are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding the future revenue growth and performance. Although ADMT believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there can be no assurance that its expectations will materialize. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to these differences include those described from time to time in ADMT’s filings, press releases and other communications. The Company assumes no obligation to update the information contained in this press release.

Andre DiMino
[email protected]

Paul N. Strickland